These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 10686005)
1. Molecular basis of Cromer blood group antigens. Lublin DM; Kompelli S; Storry JR; Reid ME Transfusion; 2000 Feb; 40(2):208-13. PubMed ID: 10686005 [TBL] [Abstract][Full Text] [Related]
2. GUTI: a new antigen in the Cromer blood group system. Storry JR; Sausais L; Hue-Roye K; Mudiwa F; Ferrer Z; Blajchman MA; Lublin DM; Ma BW; Miquel JF; Nervi F; Pereira J; Reid ME Transfusion; 2003 Mar; 43(3):340-4. PubMed ID: 12675719 [TBL] [Abstract][Full Text] [Related]
3. Molecular mapping of the Cromer blood group Cra and Tca epitopes of decay accelerating factor: toward the use of recombinant antigens in immunohematology. Telen MJ; Rao N; Udani M; Thompson ES; Kaufman RM; Lublin DM Blood; 1994 Nov; 84(9):3205-11. PubMed ID: 7524769 [TBL] [Abstract][Full Text] [Related]
5. Three new high-prevalence antigens in the Cromer blood group system. Hue-Roye K; Lomas-Francis C; Belaygorod L; Lublin DM; Barnes J; Chung A; Fung-Kee-Fung K; Kinney J; Goldman-Lavi R; Yahalom V; Poole J; Ivankovic Z; Alcantara D; Bekavac M; Cepulic BG; Velliquette RW; Mason R; Reid ME Transfusion; 2007 Sep; 47(9):1621-9. PubMed ID: 17725726 [TBL] [Abstract][Full Text] [Related]
6. Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes. Lublin DM; Mallinson G; Poole J; Reid ME; Thompson ES; Ferdman BR; Telen MJ; Anstee DJ; Tanner MJ Blood; 1994 Aug; 84(4):1276-82. PubMed ID: 7519480 [TBL] [Abstract][Full Text] [Related]
7. Hemagglutination inhibition of Cromer blood group antibodies with soluble recombinant decay-accelerating factor. Daniels GL; Green CA; Powell RM; Ward T Transfusion; 1998 Apr; 38(4):332-6. PubMed ID: 9595014 [TBL] [Abstract][Full Text] [Related]
8. SERF: a new antigen in the Cromer blood group system. Banks J; Poole J; Ahrens N; Seltsam A; Salama A; Hue-Roye K; Storry JR; Palacajornsuk P; Ma BW; Lublin DM; Reid ME Transfus Med; 2004 Aug; 14(4):313-8. PubMed ID: 15285728 [TBL] [Abstract][Full Text] [Related]
9. Decay-accelerating factor (CD55) deficiency phenotypes in Japanese. Daniels GL; Green CA; Mallinson G; Okubo Y; Hori Y; Kataoka A; Kaihara M Transfus Med; 1998 Jun; 8(2):141-7. PubMed ID: 9675792 [TBL] [Abstract][Full Text] [Related]
10. Novel molecular basis of an Inab phenotype. Hue-Roye K; Powell VI; Patel G; Lane D; Maguire M; Chung A; Reid ME Immunohematology; 2005; 21(2):53-5. PubMed ID: 15954804 [TBL] [Abstract][Full Text] [Related]
11. The Cromer blood group system: a review. Storry JR; Reid ME; Yazer MH Immunohematology; 2010; 26(3):109-18. PubMed ID: 21214297 [TBL] [Abstract][Full Text] [Related]
12. Molecular cloning and characterization of decay-accelerating factor deficiency in Cromer blood group Inab phenotype. Wang L; Uchikawa M; Tsuneyama H; Tokunaga K; Tadokoro K; Juji T Blood; 1998 Jan; 91(2):680-4. PubMed ID: 9427725 [TBL] [Abstract][Full Text] [Related]
13. Cromer-related antigens--blood group determinants on decay-accelerating factor. Daniels G Vox Sang; 1989; 56(4):205-11. PubMed ID: 2474898 [TBL] [Abstract][Full Text] [Related]
14. The Cromer blood group system: a review. Storry JR; Reid ME Immunohematology; 2002; 18(4):95-103. PubMed ID: 15373545 [TBL] [Abstract][Full Text] [Related]
15. Dr(a-) polymorphism of decay accelerating factor. Biochemical, functional, and molecular characterization and production of allele-specific transfectants. Lublin DM; Thompson ES; Green AM; Levene C; Telen MJ J Clin Invest; 1991 Jun; 87(6):1945-52. PubMed ID: 1710232 [TBL] [Abstract][Full Text] [Related]
16. 3D analysis of CROMER (DAF) and a new antigen CRAG. Floch A; Vege S; Hue-Roye K; Hamilton JR; Williams LA; Choate J; Lomas-Francis C; Westhoff CM Blood Transfus; 2022 Nov; 20(6):483-488. PubMed ID: 35175190 [TBL] [Abstract][Full Text] [Related]
17. Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF. Telen MJ; Hall SE; Green AM; Moulds JJ; Rosse WF J Exp Med; 1988 Jun; 167(6):1993-8. PubMed ID: 2455016 [TBL] [Abstract][Full Text] [Related]
18. The Cromer blood group system: an update. Storry JR; Lomas-Francis C Immunohematology; 2021 Sep; 37(3):118-121. PubMed ID: 34591381 [TBL] [Abstract][Full Text] [Related]
19. Analysis of SERF in Thai blood donors. Palacajornsuk P; Hue-Roye K; Nathalang O; Tantimavanich S; Bejrachandra S; Reid ME Immunohematology; 2005; 21(2):66-9. PubMed ID: 15954807 [TBL] [Abstract][Full Text] [Related]
20. Biochemical studies on red blood cells from a patient with the Inab phenotype (decay-accelerating factor deficiency). Reid ME; Mallinson G; Sim RB; Poole J; Pausch V; Merry AH; Liew YW; Tanner MJ Blood; 1991 Dec; 78(12):3291-7. PubMed ID: 1720702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]